ArticleScientific reports2026
Modulation of PDX1 gene expression and glycemic control by Citrullus lanatus in experimental type 2 diabetes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a major global health burden characterized by hyperglycemia, oxidative stress, and progressive pancreatic β-cell dysfunction. Despite the availability of conventional therapies, the need for safer and more effective alternatives persists. Citrullus lanatus (African watermelon) is a fruit rich in bioactive compounds with reported antihyperglycemic and antioxidant properties. This study investigated the modulatory effects of C. lanatus juice on pancreatic and duodenal homeobox 1 (PDX1) gene expression and glycemic control in fortified-diet-fed streptozotocin-induced diabetic Wistar rats. Thirty-six rats weighing 90-110 g, were randomized into six groups: normal control (NMC), diabetic control (DBC), metformin-treated diabetic rats (DBM, 500 mg/kg), and diabetic rats treated with C. lanatus juice at 200 mg/kg (DBCL1), 500 mg/kg (DBCL2), and 1000 mg/kg (DBCL3). Animals were pre-fed either normal or fortified diets prior to diabetes induction with streptozotocin (35 mg/kg). Following 14 days of treatment, blood and pancreatic tissues were analyzed for glycemic, antioxidant, and molecular parameters. C. lanatus juice significantly (p < 0.05) reduced fasting blood glucose in a dose-dependent manner, with the greatest effect observed in DBCL3. Antioxidant enzymes (catalase, superoxide dismutase, and glutathione peroxidase) were significantly increased, while malondialdehyde levels were reduced in all treated groups. Notably, PDX1 gene expression was markedly upregulated (p < 0.05) in C. lanatus-treated rats, accompanied by improved insulin, C-peptide, and HDL levels. These findings suggest that C. lanatus juice exerts antidiabetic effects that are associated with increased PDX1 mRNA expression, improved glycemic control, and reduced oxidative stress, supporting a potential role for transcriptional modulation of β-cell function, highlighting its potential as a functional dietary intervention for type 2 diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.